{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016387","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2025-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.534086+00:00","generated_at":"2026-05-18T19:17:48.864135+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%","bullets":["Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.","92% of readings in green zone of Diabetes Technology Society Error Grid, none in unsafe zones.","Ten participants with Type 1 or Type 2 diabetes; device implanted via subclavian vein, monitored 4 days.","Glucotrack expects to initiate long-term early feasibility study in Q3 2025.","OneTwo Analytics applied AI/ML analytics to validate performance."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016387","json":"https://secwatch.observer/filing/0001641172-25-016387.json","markdown":"https://secwatch.observer/filing/0001641172-25-016387.md","text":"https://secwatch.observer/filing/0001641172-25-016387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225016387/0001641172-25-016387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225016387/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T19:17:48.864135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}